Zenlabs Ethica Ltd (ZENLABS) is currently trading at 26.87 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zenlabs Ethica Limited is a pharmaceutical contract manufacturer and marketer that develops, markets and exports a wide portfolio of branded formulations across multiple therapeutic segments; the company traces its incorporation to 1993 and adopted the current name in 2016-17. For the quarter ended 30 June 2026 Zenlabs Ethica reported total income of 1,417.72 and revenue from operations of 1,417.66, a sequential increase from the prior quarter, but delivered a pre-tax loss of (55.55) and net loss of (57.12), with basic diluted EPS of (0.88). The company positions itself among India’s top 10 pharmaceutical contract manufacturing firms, offering over 600 products across gastrointestinal, anti-diabetic, anti-hypertensive, anti-infective, nutraceuticals and other segments while maintaining export relationships backed by a Canada-based strategic partner. Operationally the quarter shows material swings in working capital: purchase of stock-in-trade and a large positive change in inventory drove expense dynamics, while employee expenses moderated sharply versus the prior quarter, indicating operational adjustments and inventory-led margin pressure. Zenlabs Ethica has signalled strategic diversification into higher-value therapeutic verticals such as neurology (and a segment described as Cytrics in 2023), suggesting management intent to expand beyond legacy generic formulations into specialty and differentiated product lines.

Over the past 52 weeks, Zenlabs Ethica Ltd has traded between a low of ₹16.50 and a high of ₹39.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zenlabs Ethica Ltd has a market capitalization of approximately 16.99. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zenlabs Ethica Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -6.69 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16.99 Cr, Zenlabs Ethica Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zenlabs Ethica Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zenlabs Ethica Ltd is -6.69. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.